Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Exploring the Genetics of Schizophrenia in Manitoba (GENES-MB)

12 juni 2026 bijgewerkt door: Kaarina Kowalec, University of Manitoba

Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba

Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Gedetailleerde beschrijving

This study aims to better understand the genetic factors involved in schizophrenia by collecting saliva samples from people with schizophrenia and individuals without psychiatric disorders across Manitoba. Researchers will use advanced genome sequencing to examine differences in genetic variation and identify genes that may contribute to schizophrenia. By combining genetic information with health and clinical data, this research will help improve our understanding of schizophrenia and support the development of more personalized approaches to treatment and care. People with schizophrenia (cases) will be recruited through participating psychosis clinics in Manitoba, review and sign a consent form, provide a saliva sample for genetic testing, allow researchers to use information already collected through the Manitoba Psychosis Registry and link it with health records. People without schizophrenia or other major psychiatric disorders (screened controls) will be screened to ensure they meet eligibility requirements, review and sign a consent form, complete questionnaires about their health, quality of life, and life experiences, provide a saliva sample for genetic testing, allow researchers to link their genetic information with health records. Objective: To understand how genes contribute to schizophrenia and psychosis by analyzing DNA samples from people with and without these conditions. Endpoints: Collection of DNA samples, identification of genetic differences associated with schizophrenia and psychosis, and understanding how these genetic factors relate to symptoms, health outcomes, and disease risk.

Studietype

Observationeel

Inschrijving (Geschat)

1500

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Naam: Kaarina Kowalec, PhD
Telefoonnummer: 204-619-5711
E-mail: kaarina.kowalec@umanitoba.ca

Studie Locaties

Canada
- Manitoba
  - Winnipeg, Manitoba, Canada, R3E0T5
    - University of Manitoba
    - Contact:
      
      Danielle Perera, MSc
      
      Telefoonnummer: 204-789-3380
      
      E-mail: mb.pr@umanitoba.ca

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

Volwassen
Oudere volwassene

Accepteert gezonde vrijwilligers

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The schizophrenia study population will consist of Manitoba residents aged 18 years and older with a clinical diagnosis of schizophrenia according to DSM-5 criteria. Participants will be recruited from the MPR, including individuals receiving care through the Early Psychosis Prevention and Intervention Service (EPPIS), Schizophrenia Treatment and Education Program (STEP), Program of Assertive Community Treatment (PACT), and Assertive Community Treatment/Flexible Assertive Community Treatment (ACT/FACT) teams. Eligible participants must be enrolled in the MPR and provide informed consent to participate in the genetic sub-study. Participants will provide saliva samples for DNA extraction and whole genome sequencing, and their genetic data will be linked with clinical, questionnaire, and provincial administrative health data to support research on the genetic basis of schizophrenia and related health outcomes.

Beschrijving

Inclusion Criteria:

Individuals aged 18 years and older,
Reside in Manitoba,
Involved in the EPPIS, STEP, PACT, ACT/FACTT clinics,
Clinical diagnosis of schizophrenia using standard DSM-5 criteria,
Previously consented and enrolled in the MPR.

Exclusion Criteria:

There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Aantal groepen / cohorten

Cohorten en interventies

Groep / Cohort
Schizophrenia (cases) The schizophrenia case group will consist of Manitoba residents aged 18 years and older who have a clinical diagnosis of schizophrenia based on standard DSM-5 criteria and who are already enrolled in the Manitoba Psychosis Registry (MPR). Participants will be recruited through psychosis-focused clinical programs in Manitoba, including the Early Psychosis Prevention and Intervention Service (EPPIS), Schizophrenia Treatment and Education Program (STEP), Program of Assertive Community Treatment (PACT), and Assertive Community Treatment/Flexible Assertive Community Treatment (ACT/FACT) teams. Cases will provide saliva samples for DNA extraction and whole genome sequencing, and genetic data will be linked with clinical information, questionnaire data, and provincial health administrative data to investigate the genetic basis of schizophrenia and related health outcomes.
Control (screened) The screened control group will consist of Manitoba residents aged 40 years and older who have no known history of psychiatric disorders. Potential controls will be identified through the Manitoba Population Research Data Repository and recruited by invitation. Individuals will be excluded if they have had contact with a psychiatric specialist or have a history of antidepressant, lithium, mood stabilizer, or antipsychotic medication use. Participants will provide saliva samples for DNA extraction and whole genome sequencing, and their genetic data will be linked with provincial health administrative data. This group will serve as a comparison population for investigating genetic differences associated with schizophrenia.
Control (unscreened) An unscreened control group of approximately 2,500 individuals from Manitoba and Saskatchewan will be included through the PrairieGen project. These participants were sequenced using the same whole genome sequencing technologies as the study participants and represent the general Prairie population. While no psychiatric screening or health administrative data linkage will be available for this group, they will provide a population-based genetic reference to improve statistical power and enhance the generalizability of genetic findings.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat	Maatregel Beschrijving	Tijdsspanne
Genetic variation associated with schizophrenia Tijdsspanne: through study completion, an average of 1 year	Identification of rare and common genetic variants through short-read and long-read whole genome sequencing. Comparison of genetic variant burden between schizophrenia cases and controls.	through study completion, an average of 1 year
Rare variant burden in schizophrenia Tijdsspanne: through study completion, an average of 1 year	Evaluation of the frequency and distribution of rare genetic variants in individuals with schizophrenia compared with controls.	through study completion, an average of 1 year
Pharmacogenetic associations Tijdsspanne: through study completion, an average of 1 year	Identification of genetic variants associated with antipsychotic treatment response and adverse drug reactions.	through study completion, an average of 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

University of Manitoba

Medewerkers

Canadian Institutes of Health Research (CIHR)

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 augustus 2026

Primaire voltooiing (Geschat)

1 april 2031

Studie voltooiing (Geschat)

1 april 2031

Studieregistratiedata

Eerst ingediend

5 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 juni 2026

Eerst geplaatst (Werkelijk)

18 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)